XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.25.2

Variable Interest Entities | 6 Months Ended
--- | ---
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Variable Interest Entities |
NOTE 14. Variable Interest Entities
Consolidated Variable Interest Entities agilon health, inc.’s consolidated assets and liabilities as of June 30, 2025 and December 31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc. agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):
| June 30, 2025 |  | December 31, 2024
Assets |  |  |
Cash and cash equivalents | $ | 57,361 |  |  | $ | 78,650 |
Restricted cash equivalents | — |  |  | 5,627 |
Receivables, net | 1,046,335 |  |  | 1,015,753 |
Prepaid expenses and other current assets, net | 31,599 |  |  | 17,725 |
Property and equipment, net | 1,114 |  |  | 1,255 |
Intangible assets, net | 43,651 |  |  | 49,406 |
Other assets, net | 5,584 |  |  | 4,790 |
Liabilities |  |  |
Medical claims and related payables | 1,042,257 |  |  | 931,664 |
Accounts payable and accrued expenses | 154,932 |  |  | 199,432 |
Other liabilities | 1,381 |  |  | 2,270 |
Risk-bearing Entities. At June 30, 2025, the Company operates 33 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations. Unconsolidated Variable Interest Entities As of June 30, 2025, the Company had 12 equity method investments (liabilities), including 10 wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of June 30, 2025 and December 31, 2024, the CMS ACO Models investments had $131.6 million and $65.2 million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company’s involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed. Equity Method Investments The following table summarizes the Company’s equity method investees (in thousands):
| June 30, 2025 |  | December 31, 2024
Equity method investments - Other(1) | $ | 9,378 |  |  | $ | 9,365 |
Equity method investments - CMS ACO Models(1) | 68,528 |  |  | 52,391 |
Equity method liabilities - CMS ACO Models(2) | (10,355) |  |  | (12,290) |
___________________________________________ (1)Included in Other assets, net in the condensed consolidated balance sheets. (2)Included in Other liabilities in the condensed consolidated balance sheets. The Company is a partner in 10 wholly-owned CMS ACO Models investments in collaboration with 13 of its physician group partners operating in 12 geographies. The combined summarized operating results of the Company’s CMS ACO Models investments are as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Medical services revenue | $ | 434,806 |  |  | $ | 446,914 |  |  | $ | 848,271 |  |  | $ | 887,074 |
Medical services expense | (401,902) |  |  | (406,921) |  |  | (753,755) |  |  | (805,713) |
Other medical expenses(1) | (17,848) |  |  | (22,268) |  |  | (54,090) |  |  | (47,673) |
Income (loss) from operations(2) | 6,396 |  |  | 11,325 |  |  | 22,609 |  |  | 20,857 |
Net income (loss)(3) | 5,395 |  |  | 9,921 |  |  | 18,072 |  |  | 15,552 |
___________________________________________ (1)The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. (2)The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. (3)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations. The combined summarized balance sheet of the Company’s CMS ACO Models investments are as follows (in thousands):
| June 30, 2025 |  | December 31, 2024
Current assets | $ | 524,238 |  |  | $ | 444,963 |
Noncurrent assets | 1,894 |  |  | 1,894 |
Total assets | 526,132 |  |  | 446,857 |
Current and total liabilities | 467,959 |  |  | 406,756 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent + Details
Name: | us-gaap_VariableInterestEntityDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration